Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
EWTX 
Edgewise Therapeutics Inc (EWTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: EWTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $37.5
1 Year Target Price $37.5
| 5 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 40.01% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.54B USD | Price to earnings Ratio - | 1Y Target Price 37.5 |
Price to earnings Ratio - | 1Y Target Price 37.5 | ||
Volume (30-day avg) 10 | Beta 0.27 | 52 Weeks Range 10.60 - 38.12 | Updated Date 08/29/2025 |
52 Weeks Range 10.60 - 38.12 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.56 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.42 | Actual -0.34 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.06% | Return on Equity (TTM) -27.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 953693622 | Price to Sales(TTM) - |
Enterprise Value 953693622 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.6 | Shares Outstanding 105346000 | Shares Floating 60533751 |
Shares Outstanding 105346000 | Shares Floating 60533751 | ||
Percent Insiders 0.44 | Percent Institutions 116.33 |
Upturn AI SWOT
Edgewise Therapeutics Inc
Company Overview
History and Background
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2017. They focus on developing orally bioavailable, small molecule therapies for severe muscle disorders. The company's evolution has been marked by preclinical development, clinical trials, and fundraising activities to support their pipeline.
Core Business Areas
- Muscle Disorder Therapeutics: Edgewise focuses on developing therapies for Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD).
Leadership and Structure
The leadership team includes experienced professionals in drug development and biotechnology. The organizational structure involves research and development, clinical operations, and corporate management functions.
Top Products and Market Share
Key Offerings
- EDG-5506: EDG-5506 is the lead product candidate, an orally administered small molecule designed to reduce muscle damage associated with DMD and BMD. Currently in clinical trials (Phase 2/3). Market share is currently 0 as product is not approved. Competitors in DMD treatment include Sarepta Therapeutics (SRPT), PTC Therapeutics (PTCT) and Solid Biosciences (SLDB).
Market Dynamics
Industry Overview
The industry is characterized by high unmet needs in rare genetic disorders. There is increasing investment in gene therapies and small molecule approaches to treat muscle diseases.
Positioning
Edgewise is positioned as a company focusing on addressing the underlying causes of muscle damage rather than just treating the symptoms, potentially providing a differentiated approach.
Total Addressable Market (TAM)
The DMD and BMD market is expected to reach several billion dollars. Edgewise is positioned to capture a portion of this TAM with a successful EDG-5506.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action for EDG-5506
- Experienced management team
- Strong preclinical and early clinical data
- Focus on high unmet medical needs
Weaknesses
- Reliance on a single lead product candidate
- Clinical trial risks and potential regulatory hurdles
- Limited commercialization experience
- Cash burn rate
Opportunities
- Potential for EDG-5506 to become a best-in-class therapy
- Expansion into other muscle disorders
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results to increase share price
Threats
- Competition from existing and emerging therapies
- Clinical trial failures
- Regulatory setbacks
- Difficulty in raising additional capital
Competitors and Market Share
Key Competitors
- Sarepta Therapeutics (SRPT)
- PTC Therapeutics (PTCT)
- Solid Biosciences (SLDB)
Competitive Landscape
Edgewise's advantages lie in its novel mechanism of action and oral bioavailability. Disadvantages include its relatively early stage of development compared to established players.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by progressing through clinical trials and raising capital. No revenue yet.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals. Analyst projections vary, but expectations are high if EDG-5506 is approved.
Recent Initiatives: Recent initiatives include advancing EDG-5506 through Phase 2/3 clinical trials and presenting data at scientific conferences.
Summary
Edgewise Therapeutics is a clinical-stage company with a promising lead drug candidate, EDG-5506, targeting DMD and BMD. The company's success hinges on positive clinical trial outcomes and regulatory approval. While the market opportunity is significant, they face competition from established players and the inherent risks associated with drug development. Their solid financial position is crucial for supporting ongoing trials, while potential for partnerships also exists.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Edgewise Therapeutics Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data is based on available information and is subject to change. Market share data is an approximation.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Edgewise Therapeutics Inc
Exchange NASDAQ | Headquaters Boulder, CO, United States | ||
IPO Launch date 2021-03-26 | President, CEO & Director Dr. Kevin Koch Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 126 | Website https://edgewisetx.com |
Full time employees 126 | Website https://edgewisetx.com | ||
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.